Pretoria – Aspen Pharmacare, Southern Africa’s largest generics manufacturer and JSE Securities Exchange listed pharmaceutical company, has announced the launch of Aspen-Stavudine – the first generic antiretroviral (ARV) drug developed and manufactured in Africa. Stephen Saad, Aspen Pharmacare Group Chief Executive Officer said “Aspen-Stavudine is the first locally developed and manufactured generic ARV which presents… Continue reading Aspen manufactures Africa’s first generic ARVs
Aspen is in a closed period from 1st July 2024 until the publication of the FY2024 results on the JSE SENS platform to be released on the 3rd September 2024.
